Open-house rebate agreement for Sarilumab
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Sarilumab, ATC L04AC14
Score d'opportunité
Pourquoi ce score ?
Opportunité
62 / 100
Complexité
48 / 100
Facteurs de risque
The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...
The notice references procurement documents and an annex, but only the notice text was provided; the full document set...
Submission deadline in 6 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2026
- Non-exclusive open-house rebate agreements for the medicinal product substance Sarilumab, ATC L04AC14.
- Supply contract for pharmaceutical products.
Afficher le résumé complet
This is an open-house pharmaceutical supply arrangement for Sarilumab (ATC L04AC14) led by AOK Bayern. It is not a competitive award procedure in the usual sense: the notice states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 2024-11-01 to 2026-10-31, with contract entry possible until 2026-09-05. Submission is allowed electronically with a qualified electronic signature or in paper form, and the notice requires German-language submission or German translation for non-German documents. No contract value is stated.
Risques
The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...
The notice references procurement documents and an annex, but only the notice text was provided; the full document set...
Submission deadline in 6 days
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.
Eligibility
- Only pharmaceutical companies are eligible as potential contract partners.
Administrative
- A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Open-house rebate agreement for Sarilumab
Single lot for non-exclusive open-house rebate agreements concerning the pharmaceutical substance Sarilumab (ATC L04AC14). The lot is for supplies and is performance-related to Germany, specifically Bavaria (DE212).
Localisation
Durée
Catégorie
Date limite
Détails des critères
Siehe kurze Beschreibung
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open house Arzneimittelrabattverträge Sarilumab, ATC L04AC14
Description TED originale
Siehe kurze Beschreibung
Détails de la procédure
- Date de publication
- 16 Sep 2024
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 557248-2024
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
62 / 100
Complexité
48 / 100
Facteurs de risque
The notice uses an open-procedure form but explicitly says the arrangement is an open-house model and not a normal proc...
The notice references procurement documents and an annex, but only the notice text was provided; the full document set...
Submission deadline in 6 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications